Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development

Hagai Tavori, Mira Rosenblat, Jacov Vaya, Michael Aviram

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Paraoxonase (PON)1 is a HDL-associated enzyme with esterase (lipolactonase)- and peroxidase-like activities that exhibits antiatherogenic properties. PON1 deficiency in mice was shown to be associated with enhanced atherosclerosis development, whereas the overexpression of human PON1 resulted in a significant reduction in atherosclerotic lesion size. Human atherosclerotic lesions contain macrophages and a variety of oxidized lipids, which can facilitate further lesion progression and arterial macrophage oxidation. PON1 interacts with the atherosclerotic lesion and with macrophages to attenuate their atherogenic properties, whereas the oxidized lesion inactivates PON1. It is of interest that, similarly to HDL-associated PON1 antioxidant properties, PON2 (which is not present in the circulation) possesses similar antioxidant/antiatherogenic characteristics towards arterial macrophage foam cells, the hallmark of early atherogenesis.

Original languageEnglish (US)
Pages (from-to)685-697
Number of pages13
JournalClinical Lipidology
Volume5
Issue number5
DOIs
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Aryldialkylphosphatase
Foam Cells
Atherosclerosis
Macrophages
Antioxidants
Esterases
Peroxidase
Lipids
Enzymes

Keywords

  • atherosclerosis
  • carotid lesion
  • foam cell
  • HDL
  • lysophosphatidylcholine
  • macrophage
  • oxidative stress
  • paraoxonase

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development. / Tavori, Hagai; Rosenblat, Mira; Vaya, Jacov; Aviram, Michael.

In: Clinical Lipidology, Vol. 5, No. 5, 10.2010, p. 685-697.

Research output: Contribution to journalArticle

@article{9ba9779cd61b4ece982daa5ef8ba2389,
title = "Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development",
abstract = "Paraoxonase (PON)1 is a HDL-associated enzyme with esterase (lipolactonase)- and peroxidase-like activities that exhibits antiatherogenic properties. PON1 deficiency in mice was shown to be associated with enhanced atherosclerosis development, whereas the overexpression of human PON1 resulted in a significant reduction in atherosclerotic lesion size. Human atherosclerotic lesions contain macrophages and a variety of oxidized lipids, which can facilitate further lesion progression and arterial macrophage oxidation. PON1 interacts with the atherosclerotic lesion and with macrophages to attenuate their atherogenic properties, whereas the oxidized lesion inactivates PON1. It is of interest that, similarly to HDL-associated PON1 antioxidant properties, PON2 (which is not present in the circulation) possesses similar antioxidant/antiatherogenic characteristics towards arterial macrophage foam cells, the hallmark of early atherogenesis.",
keywords = "atherosclerosis, carotid lesion, foam cell, HDL, lysophosphatidylcholine, macrophage, oxidative stress, paraoxonase",
author = "Hagai Tavori and Mira Rosenblat and Jacov Vaya and Michael Aviram",
year = "2010",
month = "10",
doi = "10.2217/clp.10.57",
language = "English (US)",
volume = "5",
pages = "685--697",
journal = "Clinical Lipidology",
issn = "1746-0875",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development

AU - Tavori, Hagai

AU - Rosenblat, Mira

AU - Vaya, Jacov

AU - Aviram, Michael

PY - 2010/10

Y1 - 2010/10

N2 - Paraoxonase (PON)1 is a HDL-associated enzyme with esterase (lipolactonase)- and peroxidase-like activities that exhibits antiatherogenic properties. PON1 deficiency in mice was shown to be associated with enhanced atherosclerosis development, whereas the overexpression of human PON1 resulted in a significant reduction in atherosclerotic lesion size. Human atherosclerotic lesions contain macrophages and a variety of oxidized lipids, which can facilitate further lesion progression and arterial macrophage oxidation. PON1 interacts with the atherosclerotic lesion and with macrophages to attenuate their atherogenic properties, whereas the oxidized lesion inactivates PON1. It is of interest that, similarly to HDL-associated PON1 antioxidant properties, PON2 (which is not present in the circulation) possesses similar antioxidant/antiatherogenic characteristics towards arterial macrophage foam cells, the hallmark of early atherogenesis.

AB - Paraoxonase (PON)1 is a HDL-associated enzyme with esterase (lipolactonase)- and peroxidase-like activities that exhibits antiatherogenic properties. PON1 deficiency in mice was shown to be associated with enhanced atherosclerosis development, whereas the overexpression of human PON1 resulted in a significant reduction in atherosclerotic lesion size. Human atherosclerotic lesions contain macrophages and a variety of oxidized lipids, which can facilitate further lesion progression and arterial macrophage oxidation. PON1 interacts with the atherosclerotic lesion and with macrophages to attenuate their atherogenic properties, whereas the oxidized lesion inactivates PON1. It is of interest that, similarly to HDL-associated PON1 antioxidant properties, PON2 (which is not present in the circulation) possesses similar antioxidant/antiatherogenic characteristics towards arterial macrophage foam cells, the hallmark of early atherogenesis.

KW - atherosclerosis

KW - carotid lesion

KW - foam cell

KW - HDL

KW - lysophosphatidylcholine

KW - macrophage

KW - oxidative stress

KW - paraoxonase

UR - http://www.scopus.com/inward/record.url?scp=78149429670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149429670&partnerID=8YFLogxK

U2 - 10.2217/clp.10.57

DO - 10.2217/clp.10.57

M3 - Article

AN - SCOPUS:78149429670

VL - 5

SP - 685

EP - 697

JO - Clinical Lipidology

JF - Clinical Lipidology

SN - 1746-0875

IS - 5

ER -